Replidyne Seeks New Partner For Orapem After Forest Backs Out Of Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Replidyne said its top priority will be clarifying the regulatory approval process for community antibiotics with FDA.
You may also be interested in...
Replidyne Shelves Faropenem Program
Potential partners may have been scared off by challenging trial designs, analyst tells “The Pink Sheet” DAILY.
Replidyne Shelves Faropenem Program
Potential partners may have been scared off by challenging trial designs, analyst tells “The Pink Sheet” DAILY.
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.